Value of combined interpretation of computed tomography response and positron emission tomography response for prediction of prognosis after neoadjuvant chemotherapy in non-small cell lung cancer

Journal of Thoracic Oncology

Volumn 5, Issue 4, 2010, Pages 497-503

  Lee, Ho Yun ^a,c   Lee, Hyun Ju ^a   Kim, Young Tae ^b   Kang, Chang Hyun ^b   Jang, Bo Gun ^a   Chung, Doo Hyun ^a   Goo, Jin Mo ^a   Park, Chang Min ^a   Lee, Chang Hyun ^a   Kang, Keon Wook ^a  

^a Seoul National University Hospital   (South Korea)

^b Xenotransplantation Research Center   (South Korea)

^c Samsung Medical Center   (South Korea)

Author keywords

FDG PET; Non small cell lung cancer; Prognosis; Response evaluation; Response evaluation criteria in solid tumor (RECIST)

Indexed keywords

CISPLATIN; FLUORODEOXYGLUCOSE F 18; PACLITAXEL;

ADJUVANT CHEMOTHERAPY; ADULT; AGED; ARTICLE; CANCER RECURRENCE; COMPUTER ASSISTED TOMOGRAPHY; FEMALE; HUMAN; KAPLAN MEIER METHOD; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROGNOSIS; TREATMENT RESPONSE;

EID: 77950985227     PISSN: 15560864     EISSN: 15561380     Source Type: Journal    
DOI: 10.1097/JTO.0b013e3181d2efe7     Document Type: Article

References (26)

1. Lara PN Jr, Redman MW, Kelly K, et al. Disease control rate at 8 weeks predicts clinical benefit in advanced non-small-cell lung cancer: results from Southwest Oncology Group randomized trials. J Clin Oncol 2008; 26:463-467. (Pubitemid 351171700)
2. Port JL, Kent MS, Korst RJ, et al. Positron emission tomography scanning poorly predicts response to preoperative chemotherapy in non-small cell lung cancer. Ann Thorac Surg 2004;77:254-259. (Pubitemid 38130021)
3. Ryu JS, Choi NC, Fischman AJ, et al. FDG-PET in staging and restaging non-small cell lung cancer after neoadjuvant chemoradiotherapy: correlation with histopathology. Lung Cancer 2002;35:179-187. (Pubitemid 34136096)
4. Akhurst T, Downey RJ, Ginsberg MS, et al. An initial experience with FDG-PET in the imaging of residual disease after induction therapy for lung cancer. Ann Thorac Surg 2002;73:259-264. (Pubitemid 34084576)
5. Cerfolio RJ, Bryant AS, Winokur TS, et al. Repeat FDG-PET after neoadjuvant therapy is a predictor of pathologic response in patients with non-small cell lung cancer. Ann Thorac Surg 2004;78:1903-1909. (Pubitemid 39556258)
6. Weber WA, Petersen V, Schmidt B, et al. Positron emission tomography in non-small-cell lung cancer: prediction of response to chemotherapy by quantitative assessment of glucose use. J Clin Oncol 2003;21:2651-2657. (Pubitemid 46606307)
7. Eschmann SM, Friedel G, Paulsen F, et al. Repeat 18F-FDG PET for monitoring neoadjuvant chemotherapy in patients with stage III nonsmall cell lung cancer. Lung Cancer 2007;55:165-171. (Pubitemid 46074221)
8. Hoekstra CJ, Stroobants SG, Smit EF, et al. Prognostic relevance of response evaluation using [18F]-2-fluoro-2-deoxy-D-glucose positron emission tomography in patients with locally advanced nonsmall-cell lung cancer. J Clin Oncol 2005;23:8362-8370. (Pubitemid 46264010)
9. Vansteenkiste JF, Stroobants SG, De Leyn PR, et al. Potential use of FDG-PET scan after induction chemotherapy in surgically staged IIIa-N2 non-small-cell lung cancer: a prospective pilot study. Ann Oncol 1998;9:1193-1198. (Pubitemid 28552808)
10. Hellwig D, Graeter TP, Ukena D, et al. Value of F-18-fluorodeoxyglucose positron emission tomography after induction therapy of locally advanced bronchogenic carcinoma. J Thorac Cardiovasc Surg 2004; 128:892-899. (Pubitemid 39575295)
11. Tanvetyanon T, Eikman EA, Sommers E, Robinson L, Boulware D, Bepler G. Computed tomography response, but not positron emission tomography scan response, predicts survival after neoadjuvant chemotherapy for respectable non-small-cell lung cancer. J Clin Oncol 2008; 26:4610-4616.
12. Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst 2000;92:205-216. (Pubitemid 30099779)
13. Young H, Baum R, Cremerius U, et al. Measurement of clinical and subclinical tumour response using [18F]-fluorodeoxyglucose and positron emission tomography: review and 1999 EORTC recommendations. Eur J Cancer 1999;35:1773-1782. (Pubitemid 29512308)
14. Junker K, Langner K, Klinke F, et al. Grading of tumour regression in non-small cell lung cancer: morphology and prognosis. Chest 2001;120: 1584-1591. (Pubitemid 33078476)
15. Dewhirst MW, Cao Y, Moeller B. Cycling hypoxia and free radicals regulate angiogenesis and radiotherapy response. Nat Rev Cancer 2008; 8:425-437. (Pubitemid 351744964)
16. Poettgen C, Theegarten D, Eberhardt W, et al. Correlation of PET/CT findings and histopathology after neoadjuvant therapy in non-small cell lung cancer. Oncology 2007;73:316-323. (Pubitemid 351862022)
17. Oremek GM, Sauer-Eppel H, Bruzdziak TH. Value of tumour and inflammatory markers in lung cancer. Anticancer Res 2007;27:1911-1915. (Pubitemid 46954697)
18. Liu-Jarin X, Stoopler MB, Raftopoulos H, et al. Histologic assessment of non-small cell lung carcinoma after neoadjuvant therapy. Mod Pathol 2003;16:1102-1108. (Pubitemid 37414204)
19. Albain KS, Rusch VW, Crowley JJ, et al. Long-term survival after concurrent cisplatin/ etoposide plus chest radiotherapy followed by surgery in bulky, stages IIIA (N2) and IIIB non-small cell lung cancer: 6-year outcomes from Southwest Oncology Group Study 8805. Proc Am Soc Clin Oncol 1999;18:467.
20. Thomas M, Rübe C, Semik M, et al. Impact of preoperative bimodality induction including twice-daily radiation on tumour regression and survival in stage III non-small-cell lung cancer. J Clin Oncol 1999;17: 1185-1193. (Pubitemid 29162942)
21. Pisters KMW, Kris MG, Gralla RJ, et al. Pathologic complete response in advanced non-small-cell lung cancer following preoperative chemotherapy: implications for the design of future non-small cell lung cancer cobined modality trials. J Clin Oncol 1993;11:1757-1762.
22. Rice TW, Adelstein DJ, Ciezki JP, et al. Short-course induction chemoradiotherapy with paclitaxel for stage III non-small-cell lung cancer. Ann Thorac Surg 1998;66:1909-1914. (Pubitemid 29087180)
23. Bueno R, Richards W, Swanson S, et al. Nodal stage after induction therapy for stage IIIA lung cancer determines survival. Ann Thorac Surg 2000;70:1826-1831. (Pubitemid 32015269)
24. Lorent N, De Leyn P, Lievens Y, et al. Long-term survival of surgically staged IIIA-N2 non-small-cell lung cancer treated with surgical combined modality approach: analysis of a 7-year prospective experience. Ann Oncol 2004;15:1645-1653. (Pubitemid 39562605)
25. Voltolini L, Luzzi L, Ghiribelli C, Paladini P, DiBisceglie M, Gotti G. Results of induction chemotherapy followed by surgical resection in patients with stage IIIA (N2) non-small cell lung cancer: the importance of the nodal down-staging after chemotherapy. Eur J Cardiothorac Surg 2001;20:1106-1112. (Pubitemid 33054071)
26. Albain KS. Induction chemotherapy or chemoradiotherapy before surgery for non-small cell lung cancer. Curr Oncol Rep 2000;2:54-63.